NANBING LI-VILLARREAL to Neoadjuvant Therapy
This is a "connection" page, showing publications NANBING LI-VILLARREAL has written about Neoadjuvant Therapy.
Connection Strength
0.029
-
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
Score: 0.029